
Paradigm’s Kurt Mussina discusses why scale should drive operational efficiency, not consolidation into single-site studies.
Seeking faster startup for cell and gene therapy studies? Sponsors can streamline IRB and IBC reviews by coordinating the committees’ activities via a vendor offering both resources in-house.






